40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
Phase 3Recruiting 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Endometriosis
Conditions
Endometriosis
Trial Timeline
Aug 15, 2024 → Aug 15, 2026
NCT ID
NCT06439524About 40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate
40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate is a phase 3 stage product being developed by Sumitomo Pharma for Endometriosis. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06439524. Target conditions include Endometriosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06439524 | Phase 3 | Recruiting |
Competing Products
20 competing products in Endometriosis